Vitreoretinal Consultants of NY is nationally recognized for research and clinical trials related to age-related macular degeneration, diabetic eye complications, and more. Not only do clinical trials play a pivotal role in the development of new and improved treatment modalities, but they also provide eligible patients with access to zero-cost retinal care. Below is a list of active trials that are currently available for enrollment, as well as a list of previous trials. For more information on our clinical trials and how to enroll, contact us today.
For more information or to inquire about clinical trials at VRC, please contact Kristen D'Amore at firstname.lastname@example.org or call 516-466-0390 ext. 222.
A First-In Human Trial to Study Safety And Tolerability Of Single Rising Intravitreal Doses
1436.0001 (HORNBILL (Open Label, Non-Randomized, Uncontrolled) And In Addition The Early Biological Response Of Multiple Rising Intravitreal Doses (Single-Masked, Randomized, Sham-Controlled) Of Bi 764524 In Panretinalphotocoagulation (PRP) Treated Proliferative Diabetic Retinopathy (PDR) Patients With Diabetic Macular Ischemia (DMI) – The Hornbill Study
Comparator Study Evaluating the Efficacy, Safety, And Pharmacokinetics Of 100 Mg/Ml Ranibizumab Delivered Via The PDS Every 24 Weeks (Q24w) Or Every 36 Weeks (Q36w)
GR40550 (PAGODA) A Randomized, Multicenter, Open-Label (Visual Assessor Masked), Active- Compared With Intravitreal Ranibizumab 0.5 Mg Injections Every 4 Weeks (Q4w) In Patients With Diabetic Macular Edema (DME) At Randomization.
Study of Patients with Neovascular Age-related Macular Degeneration or Diabetic Retinopathy
NAB LI: Serum Anti-AAV8 Neutralizing Antibody Assessment
Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard-Of-Care for the Prevention of Proliferative Vitreoretinopathy
ADX-2191: A Multicenter, Randomized, Controlled, Prospective, Adaptive Phase 3
GR40973 (GALLEGO) A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection Controlled Study of The Safety, Tolerability, And Evidence Of Activity Of Intravitreal Injection Of RO7171009 In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration
GYX01AMD (GTSCOPE TMC) A Study of Disease Progression in Genetically Defined Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
ISEE2008 (GATHER 2) A Phase 3 Multicenter, Randomized, Double-Masked, Sham Controlled Clinical Trial To Assess The Safety And Efficacy Of Intravitreal Administration Of Zimura™ (Complement C5 Inhibitor) In Patients With Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
NGM621-GA-201 (CATALINA) A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
SAGA: A Phase 2/3 Multicenter, Randomized, Double Masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration
APL2-303 (DERBY) A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
KHB-1801 (PANDA 1) A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration
KHB-1802 (PANDA 2) A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration
GR40306 (TENAYA) A Phase III, Multicenter, Randomized, Double-Masked, Active- Comparator Controlled Study to Evaluate The Efficacy And Safety Of Faricimab In Patients With Neovascular Age-Related Macular Degeneration
GR40548 (ARCHWAY) A Phase III, Multicenter, Randomized, Visual Assessor Masked, Active-Comparator Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration
VGFTe (HD)-AMD-1905 (CANDELA) A Randomized, Single-Masked, Active-Controlled Phase 2 Study of The Safety, Tolerability, And Efficacy Of Repeated Doses Of High-Dose Aflibercept In Patients With Neovascular Age-Related Macular Degeneration
20968- (PULSAR) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
GR40349 (YOSEMITE) A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema